- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05044611
AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium (AMIND)
AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium: a Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients will be referred to the nephrology or the renal physiology department for the usual follow-up of the lithium treatment. After verification of eligilibity criteria, information and collection of consent, patient will be randomized.
During the first phase, patients will be randomized in two parallel groups: the experimental arm will receive 5mg of amiloride twice daily during 2 months and the control arm will receive a placebo twice daily during 2 months.
Measures of fasting urine osmolality will be performed at baseline, 2 months, at 6 months and at 12 months, in order to compare the difference of urine osmolality before and after treatment between the two-randomization arms. Other baseline explorations are as follows: mean number of nocturnal voids, SF-36 questionnaire, thirst intensity and distress scales, YMRS/MADRS mood scale, GAD7 anxiety scale, PSQI sleep scale, GFR measurement and estimation, 24h urine for the quantification of the polyuria and osmolality, plasma and erythrocyte lithium level, serum osmolality, natremia, kaliemia, urea, chlore level, complete blood count, plasma copeptine and vasopressin.
A nephrologist visit will take place 15 days after the initiation of the treatment along with a new measure of plasma lithium level.
Patients will be evaluated at 1 month only if a change in posology is required after the first measurement at day 15 and then at 2, 6 and 12 months.
In parallel, patients will be evaluated by at the psychiatry clinic at 1 month, 2, 6 and 12 months, and in any condition requiring additional visit as usual in standard care (follow-up of anxiety, sleepiness, suicidal ideation, depression).
After the completion of this first phase, the open label second phase will begin. Unblinding the trial will allow the treatment allocation being available for the participants and health care professionals. Amiloride will be continued in participants in the experimental group, and the remaining participants will be followed-up without treatment. This phase will last for 10 months (total trial duration: 12 months).
At one year, renal functions (GFR, urine concentration and 24h urine production) will be assessed along with report of events including hospital admission.
The safety of the experimental treatment will be assessed by regular evaluations of plasma lithium and potassium level, beginning at 2 weeks after treatment initiation and after 2 months. The main risk of amiloride is hyperkalemia, which occurs in patients with severe renal insufficiency. These patients will not be included in our study. Otherwise, the treatment is generally safe and well-tolerated. Plasma lithium level will be measured at the first month clinical evaluation if a change in posology is required after the first measurement at day 15.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: VRTOVSNIK Francois, Pr
- Phone Number: 01 40 25 71 01
- Email: francois.vrtovsnik@aphp.fr
Study Contact Backup
- Name: FLAMANT Martin
- Phone Number: 01 40 25 88 00
- Email: martin.flamant@aphp.fr
Study Locations
-
-
-
Créteil, France
- Recruiting
- Néphrologie, Hôpital Henri-Mondor
-
Contact:
- STEHLE Thomas
- Email: thomas.sethle@aphp.fr
-
Paris, France
- Active, not recruiting
- Néphrologie, Hopital Bichat
-
Paris, France
- Recruiting
- Physiologie Explorations fonctionnelles multidisciplinaires, Hôpital Bichat
-
Contact:
- LAHENS Alexandre
- Email: alexandre.lahens@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults between 18 and 70 years (age ≥ 18 years and <70 years)
- Patient with bipolar disorder
- Patient treated with lithium for at least 5 years
- Patient with a urine concentration defect defined by a maximal urine osmolality < 600 mOsm/kg
- Woman of childbearing age agreeing to use an efficient contraceptive method for 12 months
Exclusion Criteria:
- Renal failure defined as eGFR < 30 ml/min/1.73m² estimated by the CKD-EPI equation
- Kalemia > 5 mmol/l
- Hypersensitivity or known allergy to amiloride
- Hypersensitivity to lactose
- Known adrenal insufficiency
- Concomitant use of other potassium-sparing treatment (e.g. spironolactone, angiotensin converting enzyme inhibitors (ACE), angiotensin II receptor (AT2R) antagonists, calcineurin inhibitors tacrolimus and ciclosporin)
- Acute ongoing infection (less than 3 days before inclusion)
- Severe heart failure (NYHA > II)
- Rhythm, conduction or repolarisation disorder present on an ECG done within 12 months prior to inclusion
- Acute phase of mood disorder
- Uncontrolled diabetes mellitus or diabetes with hyporeninism hypoaldosteronism
- Potassium supplements
- Use of heparins
- Use of trimethoprim
- Cirrhosis
- Oedemas
- Previous use of amiloride use in the 6 months prior to randomisation)
- Pregnant or breastfeeding women
- Participation in another clinical study involving investigational medicinal product or patient being in the exclusion period at the end of a previous study
- Patient refusal to participate
- Non-affiliation to a social security regimen or CMU
- Patient under State Medical Aid
- Subject deprived of freedom, subject under a legal protective measure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Amiloride
the experimental arm will receive 5mg of amiloride twice daily during 2 months
|
Amiloride is a blocker of ENaC that is administered patients with various disorders, such as primary or secondary hyperaldosteronism. It does not have the market authorization in the indication of lithium-induced NDI. Dose : 5 mg Pharmaceutical form: Tablets Daily Posology : 10 mg Route of administration : oral Procedures and duration of treatment: 2 months during the double blinded phase and 10 additional months for the open label phase |
Placebo Comparator: Placebo
the control arm will receive a placebo twice daily during 2 months
|
Route of administration : oral the control arm will receive a placebo twice daily during 2 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The main objective of this study is demonstrating the efficacy of amiloride to reduce the urine concentration defect in patients treated by lithium and presenting a nephrogenic diabetes insipidus after 2 months of treatment.
Time Frame: 2 month after randomization
|
The primary endpoint is the percentage change in maximal urine osmolality before and after 2 months of treatment
|
2 month after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Demonstrate the efficacy of amiloride to reduce nocturia
Time Frame: 2 months after randomization and 12 months after randomization
|
Difference in mean number of nocturnal voids
|
2 months after randomization and 12 months after randomization
|
Demonstrate the efficacy of amiloride to reduce the sensation of thirst
Time Frame: 2 months after randomization and 12 months after randomization
|
Difference in mean number of nocturnal voids
|
2 months after randomization and 12 months after randomization
|
Demonstrate the efficacy of amiloride to reduce polyuria
Time Frame: 2 months after randomization and 12 months after randomization
|
Presence of polyuria (defined as a daily urine output > 3 L/day)
|
2 months after randomization and 12 months after randomization
|
Demonstrate the efficacy of amiloride to increase quality of life
Time Frame: 2 months after randomization and 12 months after randomization
|
Difference in Quality-of-life scale score (SF36)
|
2 months after randomization and 12 months after randomization
|
Demonstrate the efficacy of amiloride to reduce the decline of eGFR after one year of treatment
Time Frame: 12 months after randomization
|
Difference in eGFR (estimated by the CKD-EPI equation based on standardized serum creatinine measurement) before and after 12 months of treatment
|
12 months after randomization
|
Evaluate the effect of amiloride in mood stability
Time Frame: 2 months after randomization and 12 months after randomization
|
Difference in Mood Scale scores YMRS
|
2 months after randomization and 12 months after randomization
|
Evaluate the effect of amiloride in circulating lithium levels stability
Time Frame: 2 months after randomization
|
Difference in residual plasma lithium levels before and after the 2 months treatment period
|
2 months after randomization
|
Evaluate the effect of amiloride in mood stability
Time Frame: 12 months after randomization
|
Total number of hospital admission for maniac or depressive relapse during 12 months of treatment
|
12 months after randomization
|
Evaluate the effect of amiloride in mood stability
Time Frame: 2 months after randomization and 12 months after randomization
|
Difference in Mood Scale MADRS
|
2 months after randomization and 12 months after randomization
|
Evaluate the effect of amiloride in mood stability
Time Frame: 2 months after randomization and 12 months after randomization
|
Difference in anxiety scale score (GAD7)
|
2 months after randomization and 12 months after randomization
|
Evaluate the effect of amiloride in mood stability
Time Frame: 2 months after randomization and 12 months after randomization
|
Difference in the Pittsburgh sleep score (PSQI)
|
2 months after randomization and 12 months after randomization
|
Collaborators and Investigators
Investigators
- Study Chair: DECHANET Aline, Mrs, Assistance Publique - Hôpitaux de Paris (AP-HP)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Mood Disorders
- Kidney Diseases
- Urologic Diseases
- Endocrine System Diseases
- Bipolar and Related Disorders
- Pituitary Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Bipolar Disorder
- Diabetes Insipidus
- Diabetes Insipidus, Nephrogenic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Sodium Channel Blockers
- Diuretics, Potassium Sparing
- Acid Sensing Ion Channel Blockers
- Epithelial Sodium Channel Blockers
- Amiloride
Other Study ID Numbers
- APHP200042
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Region StockholmKarolinska InstitutetRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder | Bipolar Affective Disorder; Remission in | Bipolar Affective Disorder, Currently Depressed, ModerateSweden
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
-
Medical University of South CarolinaMilken InstituteCompletedBipolar Disorder | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
Mayo ClinicCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
Myriad Genetic Laboratories, Inc.University of MinnesotaCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
Clinical Trials on Anhydrous Amiloride Hydrochloride
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions
-
Children's Hospital of Orange CountyRecruiting
-
Jonsson Comprehensive Cancer CenterBreast Cancer Research Foundation; MetVital, Inc.RecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic... and other conditionsUnited States
-
Terra Biological LLCBateman Horne CenterEnrolling by invitationFatigue | Chronic Fatigue Syndrome | Myalgic EncephalomyelitisUnited States
-
University of SaskatchewanUniversity of Chicago; Emory University; University of Alberta; University of Calgary and other collaboratorsCompleted
-
GlaxoSmithKlineCompleted
-
Terra Biological LLCBateman Horne CenterRecruitingFatigue Syndrome, Chronic | Post-COVID-19 SyndromeUnited States
-
Instituto de Investigación Hospital Universitario...Alicorp S.A.A.Completed
-
Eurofarma Laboratorios S.A.UnknownArterial HypertensionBrazil
-
FDA Office of Orphan Products DevelopmentUniversity of North CarolinaCompleted